Acuta Capital Partners’s Sutro Biopharma STRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$407K Sell
25,290
-244,961
-91% -$5.41M 0.31% 32
2026
Q2
$8.97M Buy
270,251
+826
+0.3% +$25.8K 6.25% 4
2026
Q1
$6.71M Buy
269,425
+201,974
+299% +$3.65M 4.73% 6
2025
Q4
$780K Buy
+67,451
New +$640K 0.53% 24
2019
Q2
– Sell
-4,550
Closed -$518K – 38
2019
Q1
$518K Hold
4,550
– – 0.25% 30
2018
Q4
$410K Buy
+4,550
New +$549K 0.31% 19

Other funds holding STRO

Acuta Capital Partners's STRO Position: Q3 2026 in Review

Acuta Capital Partners reduced its Sutro Biopharma (STRO) stake by 91% in Q3 2026, selling an estimated $5.41M and leaving 25,290 shares worth $407K. The position accounts for 0.31% of the portfolio, ranked #32.

Acuta Capital Partners first reported a position in STRO in Q4 2018 and has held it in 6 quarters since. The position peaked at $8.97M in Q2 2026. 104 funds tracked by Wall St. Rank hold STRO as of Q3 2026.

  • Acuta Capital Partners held 25,290 shares of Sutro Biopharma worth $407K as of Q3 2026.
  • Acuta Capital Partners sold 244,961 Sutro Biopharma shares in Q3 2026, an estimated $5.41M.
  • Sutro Biopharma made up 0.31% of Acuta Capital Partners's portfolio in Q3 2026, its #32 holding.
  • Acuta Capital Partners first reported a position in Sutro Biopharma in Q4 2018 and has held it in 6 quarters since.
  • Acuta Capital Partners's Sutro Biopharma position peaked at $8.97M in Q2 2026.
  • 104 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2026.

Based on Acuta Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.